Alpha Or Leukocyte Patents (Class 424/85.7)
-
Patent number: 8425896Abstract: This invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and therefore is useful to prevent and treat viral diseases and cancers. This invention also provides an artificial gene which codes for the super-compound interferon or its equivalent. Finally, this invention provides methods to produce recombinant super-compound interferon or its equivalent and various uses of said interferon.Type: GrantFiled: February 1, 2011Date of Patent: April 23, 2013Assignee: Sichuan Biotechnology Research CenterInventors: Guangwen Wei, Rongbing Guo, Renhuai Zhang
-
Publication number: 20130095064Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections.Type: ApplicationFiled: October 12, 2012Publication date: April 18, 2013Applicant: Idenix Pharmaceuticals, Inc.Inventor: Idenix Pharmaceuticals, Inc.
-
Publication number: 20130095034Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugate compositions in therapeutic and/or diagnostic methods.Type: ApplicationFiled: November 27, 2012Publication date: April 18, 2013Applicant: IMMUNOMEDICS INC.Inventor: Immunomedics Inc.
-
Publication number: 20130089520Abstract: Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR7, —NH—SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl; R4 is aryl or Het; n is 3, 4, 5, or 6; R5 is halo, C1-6alkyl, hydroxy, C1-6alkoxy, phenyl, or Het; R6 is C1-6alkoxy, or dimethylamino; R7 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R8 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogeType: ApplicationFiled: November 28, 2012Publication date: April 11, 2013Applicants: MEDIVIR AB, TIBOTEC PHARMACEUTICALS LTD.Inventors: TIBOTEC PHARMACEUTICALS LTD., MEDIVIR AB
-
Patent number: 8409562Abstract: The current invention describes chimeric vaccine antigens against the virus that causes the Classic Swine Fever (CSFV). Such vaccine antigens are based on viral subunits coupled to proteins able to stimulate cellular and humoral immune system. Chimeric antigens can be produced in expression systems that guarantee a correct tertiary structure folding of the chimeric molecules, which constitute the essence of the current invention. The vaccine formulations containing such chimeric antigens induce an early and potent immune response on vaccinated pigs and confer full protection against CSFV. Moreover, the resultant vaccine formulations prevent the viral transmission from sows to their offspring. The chimeric antigens, as well as the resultant vaccine formulations, can be applied in animal health as vaccines for preventive use in swine.Type: GrantFiled: February 28, 2007Date of Patent: April 2, 2013Assignees: Centro de Ingenieria Genetica y Biotecnologia, Centro Nacional de Sanidad AgropecuariaInventors: Jorge Roberto Toledo Alonso, Oliberto Sánchez Ramos, Maritza Isidra Barrera Valle, Nancy Elena Figueroa Baile, Yanet Prieto Carratala, Maria Pilar Rodriguez Molto, Maria Teresa Frias Lepoureau, Carlos Guillermo Borroto Nordelo
-
Publication number: 20130078183Abstract: Disclosed herein are compositions and methods of use comprising hexavalent DNL complexes. Preferably, the complexes comprise anti-CD20 and/or anti-CD22 antibodies or fragments thereof. More preferably, the anti-CD20 antibody is veltuzumab and the anti-CD22 antibody is epratuzumab. Administration of the subject hexavalent DNL complexes induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease. In most preferred embodiments, the DNL complexes increase levels of phosphorylated p38 and PTEN, decrease levels of phosphorylated Lyn, Akt, ERK, IKK?/? and I?B?, increase expression of RKIP and Bax and decrease expression of Mcl-1, Bcl-xL, Bcl-2, and phospho-BAD in target cells. The subject DNL complexes show EC50 values for inhibiting tumor cell growth in the low nanomolar or even sub-nanomolar concentration range.Type: ApplicationFiled: November 5, 2012Publication date: March 28, 2013Applicant: IBC PHARMACEUTICALS, INC.Inventor: IBC Pharmaceuticals, Inc.
-
Publication number: 20130078217Abstract: The present invention relates to 2?-chloroacetylenyl-substituted nucleoside derivatives of the general formula (I): As well as pharmaceutical compositions comprising such compounds and methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnormal cellular proliferation, comprising administering said compounds or compositions. In addition, the present invention includes processes for the preparation of such compounds, and the related ?-D and ?-L-nucleoside derivatives.Type: ApplicationFiled: September 21, 2012Publication date: March 28, 2013Inventors: Guoqiang Wang, In Jong Kim, Yat Sun Or
-
Publication number: 20130078218Abstract: The invention provides methods for treating hepatitis C viral infections and related viral infections, as well as compounds and compositions that are useful for treating such infections.Type: ApplicationFiled: March 26, 2012Publication date: March 28, 2013Inventors: Yarlagadda S. Babu, Pooran Chand, Minwan Wu, Pravin L. Kotian, V. Satish Kumar, Tsu-Hsing Lin, Yahya El-Kattan, Ajit K. Ghosh
-
Publication number: 20130078182Abstract: Substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments are disclosed. They are useful for treatment of B-cell disorders, such as B-cell malignancies and autoimmune diseases, as well as GVHD, organ transplant rejection, and hemolytic anemia and cryoglobulinemia. Substitution of an aspartate residue at Kabat position 101 of CDR3 VH (CDRH3), produces improved therapeutic properties, including decreased dissociation rates and improved CDC activity, apoptosis, B-cell depletion and therapeutic efficacy at very low dosages.Type: ApplicationFiled: September 14, 2012Publication date: March 28, 2013Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Chien-Hsing Chang, Hans J. Hansen
-
Publication number: 20130071354Abstract: Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.Type: ApplicationFiled: November 16, 2012Publication date: March 21, 2013Applicant: Gilead Sciences, Inc.Inventor: Gilead Sciences, Inc.
-
Publication number: 20130071352Abstract: Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.Type: ApplicationFiled: November 13, 2012Publication date: March 21, 2013Applicant: IDENIX PHARMACEUTICALS, INC.Inventor: Idenix Pharmaceuticals, Inc.
-
Publication number: 20130064793Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: September 11, 2012Publication date: March 14, 2013Applicant: IDENIX PHARMACEUTICALS, INC.Inventors: Dominique SURLERAUX, Cyril B. DOUSSON, David DUKHAN, Claire PIERRA
-
Publication number: 20130064794Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: September 11, 2012Publication date: March 14, 2013Applicant: IDENIX PHARMACEUTICALS, INC.Inventors: Dominique Surleraux, Cyril B. Dousson, Gilles Gosselin, David Dukhan, Claire Pierra, Jerome Peyronnet
-
Publication number: 20130058894Abstract: Disclosed are therapeutic protein-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods.Type: ApplicationFiled: April 27, 2012Publication date: March 7, 2013Applicant: Selecta Biosciences, Inc.Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
-
Publication number: 20130058896Abstract: The invention relates to an isolated amino acid that can act as an antagonist to FGF signaling, comprising at least a portion of the FGF protein amino acid sequence, and including a mutation in either a) the integrin ?v?3 binding region of FGF-1; or b) the FGFR binding region of FGF-1.Type: ApplicationFiled: March 30, 2012Publication date: March 7, 2013Applicant: The Regents of the University of CaliforniaInventors: Yoshikazu Takada, Seiji Mori
-
Publication number: 20130052163Abstract: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.Type: ApplicationFiled: August 28, 2012Publication date: February 28, 2013Applicant: Theraclone Sciences, Inc.Inventor: Po-Ying Chan-Hui
-
Publication number: 20130052240Abstract: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of waste in the DMO. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure.Type: ApplicationFiled: October 22, 2012Publication date: February 28, 2013Applicant: Medgenics Medical Israel Ltd.Inventor: Medgenics Medical Israel Ltd.
-
Publication number: 20130052237Abstract: A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.Type: ApplicationFiled: August 29, 2012Publication date: February 28, 2013Applicant: INTARCIA THERAPEUTICS, INC.Inventors: Rom Ezer Eliaz, Yuanpeng Zhang, Catherine Manya Rohloff, Eric William Weeks, Gunjan Junnarkar
-
Publication number: 20130039887Abstract: Disclosed herein are methods for identifying compounds for the treatment of viral infection, including RNA viral infection and uses of the compounds as pharmaceutical compositions. The identified compounds modulate the RIG-I pathway in vertebrate cells.Type: ApplicationFiled: April 20, 2011Publication date: February 14, 2013Applicant: KINETA, INC.Inventors: Shawn P. Iadonato, Kristin Bedard, Michael Gale
-
Publication number: 20130034522Abstract: A method of improving the pharmacokinetics of VX-222 in a patient infected with HCV comprises co-administering VX-222 and VX-950 to the patient. A method of treating a patient infected with HCV comprises administering VX-222 and VX-950 to the patient, wherein VX-222 is in an amount of about 20 mg to about 400 mg, and wherein VX-950 is in an amount of about 100 mg to about 1,500 mg. A method of treating a patient infected with HCV comprises administering a therapeutically effective amount of VX-222, wherein VX-222 is administered at an amount of about 20 mg to about 2,000 mg once a day.Type: ApplicationFiled: July 27, 2012Publication date: February 7, 2013Applicant: Vertex Pharmaceuticals IncorporatedInventors: Maria Rosario, Nathalie Chauret, Shelley George, Tara Lynn Kieffer, Margaret James Koziel, Olivier Nicolas, Louise Proulx
-
Publication number: 20130034519Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.Type: ApplicationFiled: September 13, 2012Publication date: February 7, 2013Inventors: Trixi BRANDL, Prakash RAMAN, Pascal RIGOLLIER, Mohindra SEEPERSAUD, Oliver SIMIC
-
Publication number: 20130034520Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: ApplicationFiled: October 12, 2012Publication date: February 7, 2013Applicant: Bristol-Myers Squibb CompanyInventor: Bristol-Myers Squibb Company
-
Patent number: 8367054Abstract: Lyophilized and stabilized formulations of PEG-Interferon alpha conjugates and the process for their preparation that reduces lyophilization cycle time and are more cost competitive.Type: GrantFiled: November 16, 2007Date of Patent: February 5, 2013Assignee: Cadila Healthcare LimitedInventors: Sanjay Bandyopadhyay, Venkatesan Natarajan, Sanjeev Kumar Mendiratta, Pankaj Ramanbhai Patel
-
Publication number: 20130028861Abstract: The present invention relates to a cytokine for use in the treatment and/or control of dependent and/or addictive behavior, in particular addiction and/or dependency to nicotine, food addiction, alcohol addiction and/or sex addiction. The present invention also relates to treatment and/or control of withdrawal and/or symptoms of withdrawal from an addiction, in particular nicotine addiction, food addiction, alcohol addiction and/or sex addiction. The present invention further relates to the induction of loss of interest or aversion to the addictive substance or behavior, such as nicotine, over-indulgence in high-calorie, high-fat foods, and to other behaviors or addictions that are hazardous to the health.Type: ApplicationFiled: January 27, 2011Publication date: January 31, 2013Applicant: IMMUNSERVICE GMBHInventor: Edith Huland
-
Publication number: 20130028859Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: ApplicationFiled: January 30, 2012Publication date: January 31, 2013Inventors: John A. Bender, Omar D. Lopez, Gan Wang, Makonen Belema, John F. Kadow
-
Patent number: 8361471Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.Type: GrantFiled: July 29, 2010Date of Patent: January 29, 2013Assignee: The Regents of the University of ColoradoInventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
-
Publication number: 20130022541Abstract: Disclosed herein are methods and compositions comprising fingolimod and anti-CD74 antibodies or fragments thereof. In preferred embodiments, the fingolimod increases the expression of CD74 in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 antibodies. The compositions and methods are of use to treat diseases involving CD74+ cells, such as cancer cells, autoimmune disease cells or immune dysfunction disease cells.Type: ApplicationFiled: July 18, 2012Publication date: January 24, 2013Applicants: IMMUNOMEDICS, INC., THE OHIO STATE UNIVERSITYInventors: Lapo Alinari, Robert A. Baiocchi, Natarajan Muthusamy, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20130022572Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.Type: ApplicationFiled: September 13, 2012Publication date: January 24, 2013Inventors: Trixi BRANDL, Prakash RAMAN, Pascal RIGOLLIER, Mohindra SEEPERSAUD, Oliver SIMIC
-
Publication number: 20130022671Abstract: Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.Type: ApplicationFiled: July 17, 2012Publication date: January 24, 2013Inventors: Paul F. Glidden, Alison J. Pilgrim, Stephen R. Hanson
-
Publication number: 20130011365Abstract: The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radio sensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects.Type: ApplicationFiled: June 19, 2012Publication date: January 10, 2013Applicant: EISAI INC.Inventors: Weizheng XU, Greg Delahanty, Ling Wei, Jie Zhang
-
Patent number: 8349802Abstract: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).Type: GrantFiled: August 29, 2011Date of Patent: January 8, 2013Assignee: Spectrum Pharmaceuticals, Inc.Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
-
Publication number: 20130004459Abstract: The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.Type: ApplicationFiled: December 15, 2009Publication date: January 3, 2013Inventors: Hugues De The, Ali Bazarbachi, Olivier Hermine
-
Publication number: 20130004457Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: ApplicationFiled: September 11, 2012Publication date: January 3, 2013Inventors: Carol Bachand, Makonen Bekema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Gan Wang, Lawrence G. Hamann
-
Publication number: 20130004415Abstract: The present invention provides peptides that home to a joint of an animal, wherein said peptide comprises an amino acid motif selected from the group consisting of NQR and ADK. Also provided are methods of treating a subject having an arthritic joint, comprising the step of administering to said subject a pharmacologically effective dose of a composition provided herein.Type: ApplicationFiled: June 29, 2012Publication date: January 3, 2013Inventors: Kamal Moudgil, Ying-hua Yang
-
Patent number: 8343477Abstract: Macrocyclic peptides are disclosed having the general formula: wherein R3, R?3, R4, R6, R?, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.Type: GrantFiled: October 25, 2007Date of Patent: January 1, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Stanley D'Andrea, Zhizhen Barbara Zheng, Paul Michael Scola
-
Publication number: 20120328569Abstract: Disclosed are compounds of formula (I) that are used as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.Type: ApplicationFiled: March 2, 2011Publication date: December 27, 2012Inventors: Casey Cameron McComas, Nigel J. Liverton, Richard Soll, Peng Li, Xuanjia Peng, Hao Wu, Frank Narjes, Joerg Habermann, Uwe Koch, Shilan Liu
-
Publication number: 20120328570Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: ApplicationFiled: September 7, 2012Publication date: December 27, 2012Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Lawrence G. Hamann
-
Publication number: 20120328568Abstract: The disclosure relates to uses of a purified or isolated lectin to kill bacteria, viruses, and other pathogens. In certain embodiments, the disclosure relates to method of treating or preventing an infection comprising administering a purified or isolated galectin to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnosed with a pathogenic infection.Type: ApplicationFiled: February 11, 2011Publication date: December 27, 2012Applicant: EMORY UNIVERSITYInventors: Richard D Cummings, Sean R. Stowell, Connie Arthur
-
Publication number: 20120321590Abstract: The invention is directed to amides of bicyclic amine compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.Type: ApplicationFiled: April 5, 2012Publication date: December 20, 2012Applicant: Anadys Pharmaceuticals, Inc.Inventors: Stephen E. Webber, Chinh V. Tran, Alan X. Xiang, Douglas E. Murphy
-
Publication number: 20120321553Abstract: Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.Type: ApplicationFiled: May 1, 2012Publication date: December 20, 2012Applicant: IMMUNOMEDICS, INC.Inventors: Li Zeng, Rohini Mitra, Edmund A. Rossi, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20120321591Abstract: The present invention provides various uses of VEGF binding peptides, including methods to treat disorders associated with abnormal angiogenesis.Type: ApplicationFiled: August 27, 2012Publication date: December 20, 2012Inventors: Venkata Ramana Doppalapudi, Jing-Yu Lai, Bin Liu, Dingguo Liu, Joel Desharnais, Abhijit Suresh Bhat, Yanwen Fu, Bryan Douglas Oates, Gang Chen, Curt William Bradshaw
-
Patent number: 8329727Abstract: The present invention relates to pharmaceutical compositions for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine prodrug having the general Formula (A) wherein the substituents are described in the specification. The invention also relates to processes for the preparation and screening of compounds according to the invention having above mentioned general Formula and their use in the treatment or prophylaxis of viral infections.Type: GrantFiled: October 13, 2009Date of Patent: December 11, 2012Assignees: Gilead Sciences, Inc., K.U. Leuven Research & DevelopmentInventors: Steven S. Bondy, Eric Davis Dowdy, Choung U. Kim, David A. Oare, Johan Neyts, Vahid Zia, Gerhard Pürstinger
-
Patent number: 8329160Abstract: The present invention relates to a method of treating cancers, especially those showing resistance to classical anti-pro liferative chemotherapy drugs. Further, the invention provides a specific interferon alpha sequential regimen for treating cancers, especially those showing resistance to classical anti-proliferative chemotherapy drugs such as stem cell driven cancers. More specifically, the invention relates to a use of IFN alpha for the preparation of a pharmaceutical formulation for the treatment of cancers wherein the pharmaceutical formulation is to be administered following a sequential administration pattern i.e. an induction period wherein a therapeutically effective amount of IFN alpha is administered, a period during which no IFN alpha is administrated and a chemotherapy period wherein a therapeutically effective amount of a chemotherapeutic agent is administered.Type: GrantFiled: June 13, 2008Date of Patent: December 11, 2012Assignee: HI-StemInventors: Andreas Trumpp, Marieke Essers
-
Publication number: 20120308516Abstract: Metallocene compounds and pharmaceutical compositions containing these metallocene compounds are disclosed and described. Methods of treating cancer employing such metallocene compounds and pharmaceutical compositions also are provided.Type: ApplicationFiled: June 5, 2012Publication date: December 6, 2012Applicant: CHEVRON PHILLIPS CHEMICAL COMPANY LPInventors: MARK L. HLAVINKA, QING YANG, MANDI MICHELLE MURPH
-
Publication number: 20120301430Abstract: Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein R1, X, Y, and Z are as defined herein, are useful for treating flaviviridae viral infections.Type: ApplicationFiled: August 10, 2012Publication date: November 29, 2012Applicant: Vertex Pharmaceuticals (Canada) IncorporatedInventors: Laval Chan Chun Kong, Sanjoy Kumar Das, Carl Poisson, Constantin G. Yannopoulos, Guy Falardeau, Louis Vaillancourt, Real Denis
-
Publication number: 20120301428Abstract: The disclosure relates to the identification of an essential Clostridium difficile gene that encodes a polypeptide with protease activity and its use in the identification of anti-microbial agents and as antigen in subunit vaccines.Type: ApplicationFiled: February 22, 2011Publication date: November 29, 2012Inventors: Brendan Wren, Lisa Dawson
-
Publication number: 20120301431Abstract: The present invention provides methods of treating (including preventing) a disease or condition associated with abnormal angiogenesis in a subject include administering a therapeutically effective amount of an AA targeting compound of the invention to the subject. The AA targeting compounds comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody.Type: ApplicationFiled: August 13, 2012Publication date: November 29, 2012Inventors: Curt Bradshaw, Abhijit Bhat, Jing Yu Lai, Venkata Doppalapudi, Dingguo Liu
-
Publication number: 20120294832Abstract: The present invention relates to a novel solid composition, useful for treating hepatitis, in particular hepatitis C, comprising at least one interferon alpha and at least one grafted poly(glutamic acid) having an average molar mass ranging from 26,000 to 40,000 g/mol, preferably approximately 33,000 g/mol and carrying grafts of alpha-tocopherol at an average molar grafting rate ranging from 4.5 to 5.5%, preferably approximately 5%, the interferon alpha and said grafted poly(glutamic acid) being present in a grafted poly(glutamic acid)/interferon alpha weight ratio ranging from 21 to 125. It also relates to the use of such a solid composition for the preparation of a liquid composition by the addition of an aqueous liquid.Type: ApplicationFiled: May 16, 2012Publication date: November 22, 2012Applicant: Flamel TechnologiesInventors: Gauthier Pouliquen, You-Ping Chan, Rémi Meyrueix, David Chognot, Roger Kravtzoff
-
Publication number: 20120294830Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.Type: ApplicationFiled: July 6, 2012Publication date: November 22, 2012Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
-
Publication number: 20120294831Abstract: The invention provides for the use of pharmaceutical compositions comprising a thiazolide in the stimulation of the immune system in a subject in need thereof, thereby preventing and/or treating viral diseases, cancer and diseases caused by intracellular protozoan infectionsType: ApplicationFiled: May 15, 2012Publication date: November 22, 2012Inventor: Jean-Francois Rossignol